Glaxosmithkline Cons patents expiration
1. Alli patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004996 | GLAXOSMITHKLINE CONS | Tetrahydrolipstatin containing compositions |
Jan, 2018
(6 years ago) | |
Drugs and Companies using ORLISTAT ingredient
Market Authorisation Date: 07 February, 2007
Treatment: NA
Dosage: CAPSULE;ORAL
ALLI family patents
2. Excedrin (migraine Relief) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972916 | GLAXOSMITHKLINE CONS | Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine |
Jul, 2017
(6 years ago) | |
Drugs and Companies using ACETAMINOPHEN; ASPIRIN; CAFFEINE ingredient
Market Authorisation Date: 14 January, 1998
Treatment: Treating migraine pain and one or more of a cluster of symptoms characteristic of a migraine attack symptoms being selected from photophobia, phonophobia nausea and functional disability
Dosage: TABLET;ORAL
EXCEDRIN (MIGRAINE RELIEF) family patents
3. Flonase Sensimist Allergy Relief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE CONS | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858596 | GLAXOSMITHKLINE CONS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US7541350 | GLAXOSMITHKLINE CONS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9320862 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Nov, 2024
(6 months from now) | |
| US8062264 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8752543 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8347879 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Jul, 2028
(4 years from now) | |
| US8147461 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Oct, 2028
(4 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Otc use: allergy symptom reliever; Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; Nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes ...
Dosage: SPRAY, METERED;NASAL
FLONASE SENSIMIST ALLERGY RELIEF family patents
4. Lamisil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6005001 (Pediatric) | GLAXOSMITHKLINE CONS | Pharmaceutical composition |
Nov, 2012
(11 years ago) | |
|
US5856355 (Pediatric) | GLAXOSMITHKLINE CONS | Pharmaceutical composition |
Nov, 2012
(11 years ago) | |
| US5681849 | GLAXOSMITHKLINE CONS | Pharmaceutical composition for topical applications |
Oct, 2014
(9 years ago) | |
|
US5681849 (Pediatric) | GLAXOSMITHKLINE CONS | Pharmaceutical composition for topical applications |
Apr, 2015
(8 years ago) | |
Drugs and Companies using TERBINAFINE ingredient
Market Authorisation Date: 29 April, 1998
Treatment: NA
Dosage: GEL;TOPICAL
LAMISIL family patents
5. Lamisil At patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5856355 (Pediatric) | GLAXOSMITHKLINE CONS | Pharmaceutical composition |
Nov, 2012
(11 years ago) | |
| US5681849 | GLAXOSMITHKLINE CONS | Pharmaceutical composition for topical applications |
Oct, 2014
(9 years ago) | |
|
US5681849 (Pediatric) | GLAXOSMITHKLINE CONS | Pharmaceutical composition for topical applications |
Apr, 2015
(8 years ago) | |
Drugs and Companies using TERBINAFINE ingredient
Market Authorisation Date: 24 July, 2006
Treatment: NA
Dosage: GEL;TOPICAL
LAMISIL AT family patents
6. Lamisil At patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5681849 | GLAXOSMITHKLINE CONS | Pharmaceutical composition for topical applications |
Oct, 2014
(9 years ago) | |
|
US5681849 (Pediatric) | GLAXOSMITHKLINE CONS | Pharmaceutical composition for topical applications |
Apr, 2015
(8 years ago) | |
Drugs and Companies using TERBINAFINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2000
Treatment: NA
Dosage: SPRAY;TOPICAL
LAMISIL AT family patents